<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075802</url>
  </required_header>
  <id_info>
    <org_study_id>TADE study</org_study_id>
    <nct_id>NCT01075802</nct_id>
  </id_info>
  <brief_title>Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms</brief_title>
  <acronym>TADE</acronym>
  <official_title>A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Sydney Local Health District</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St George Hospital, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western Sydney Local Health District</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tamoxifen is an important drug for the treatment of breast cancer. Used adjuvantly after&#xD;
      operation in early breast cancer, tamoxifen reduces annual recurrence rate by half and cancer&#xD;
      death by one third. Used preventatively it also reduces the risk of breast cancer by 50% in&#xD;
      women at high risk for developing the disease Tamoxifen needs to be activated in the body to&#xD;
      an active form called endoxifen, mainly by the enzyme called CYP2D6. Patients have variable&#xD;
      capability to activate tamoxifen due to variable function of this enzyme. Studies showed&#xD;
      clear correlation of specific genetic variant of CYP2D6 with endoxifen blood levels. It is&#xD;
      estimated that up to 25% Caucasian population have reduced or even absent CYP2D6 function.&#xD;
      More recently, there were studies that showed the correlation with genetic variant of CYP2D6&#xD;
      and breast cancer relapse in early breast cancer patients treated with tamoxifen. Food and&#xD;
      Drug Authority (FDA) in America and recommended checking CYP2D6 genotype in patients&#xD;
      receiving tamoxifen treatment, but they did not specify how to interpret the genotype results&#xD;
      and what kind actions to take in patient with adverse genotype. The aim of the investigators&#xD;
      study is to see if increasing tamoxifen in patients with genetic polymorphism of CYP2D6 will&#xD;
      increase endoxifen level to the same range of most patients who have wild type (normal&#xD;
      functional)CYP2D6.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of genotype of CYP2D on plasma and serum concentration of tamoxifen and its metabolites, with consequent recommendation for dosage adjustment</measure>
    <time_frame>dose escalation over 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To test whether Tamoxifen dose escalation in patients with genetic polymorphism of CYP2D6 will increase endoxifen blood levels to a target level</measure>
    <time_frame>Dose escalation over 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate tamoxifen and its metabolites concentration with tamoxifen side effects</measure>
    <time_frame>dose escalation over 40 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Breast Cancer</condition>
  <condition>CYP2D6 Polymorphism</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of tamoxifen in patients with low endoxifen levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Histologically or cytologically confirmed early, locally advanced or metastatic breast&#xD;
             cancer&#xD;
&#xD;
          -  Oestrogen receptor positive&#xD;
&#xD;
          -  About to start tamoxifen treatment or already on tamoxifen 20mg daily&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent chemotherapy or radiotherapy&#xD;
&#xD;
          -  Treatment with medications that may alter cytochrome P450 (CYP450)3A4/5 and CYP2D6&#xD;
             activities&#xD;
&#xD;
          -  History of thrombosis&#xD;
&#xD;
          -  History of non-compliance with previous or current treatment;&#xD;
&#xD;
          -  Medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Gurney, MBBS,FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>South West Sydney Local Health District</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Cancer Care Centre</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Sydney Local Health District</investigator_affiliation>
    <investigator_full_name>Howard Gurney</investigator_full_name>
    <investigator_title>A/Prof Howard Gurney</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Endoxifen</keyword>
  <keyword>polymorphism of CYP2D6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

